116 related articles for article (PubMed ID: 1933851)
1. In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy.
el-Tahtawy A; Wolf W
Cancer Res; 1991 Nov; 51(21):5806-12. PubMed ID: 1933851
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by 19F-magnetic resonance spectroscopy.
Katzir I; Shani J; Wolf W; Chatterjee-Parti S; Berman E
Cancer Invest; 2000; 18(1):20-7. PubMed ID: 10701363
[TBL] [Abstract][Full Text] [Related]
3. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.
Hull WE; Port RE; Herrmann R; Britsch B; Kunz W
Cancer Res; 1988 Mar; 48(6):1680-8. PubMed ID: 3125967
[TBL] [Abstract][Full Text] [Related]
4. pH dependence of 5-fluorouracil uptake observed by in vivo 31P and 19F nuclear magnetic resonance spectroscopy.
Guerquin-Kern JL; Leteurtre F; Croisy A; Lhoste JM
Cancer Res; 1991 Oct; 51(20):5770-3. PubMed ID: 1913695
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive spectroscopic analysis of fluoropyrimidine metabolism in cultured tumor cells.
Keniry M; Benz C; Shafer RH; James TL
Cancer Res; 1986 Apr; 46(4 Pt 1):1754-8. PubMed ID: 3456267
[TBL] [Abstract][Full Text] [Related]
6. [In-vivo 19F-MRS study of 5-fluorouracil (5-FU) metabolism on tumors].
Harada M; Nishitani H; Shirahama T; Koga K; Miura I
Gan To Kagaku Ryoho; 1991 Jan; 18(1):75-80. PubMed ID: 1899014
[TBL] [Abstract][Full Text] [Related]
7. In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy.
Adams ER; Leffert JJ; Craig DJ; Spector T; Pizzorno G
Cancer Res; 1999 Jan; 59(1):122-7. PubMed ID: 9892196
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging.
Aboagye EO; Artemov D; Senter PD; Bhujwalla ZM
Cancer Res; 1998 Sep; 58(18):4075-8. PubMed ID: 9751613
[TBL] [Abstract][Full Text] [Related]
9. Novel non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS). Studies in the SCCVII/C3H murine model.
Papadopoulou MV; Pouremad R; Bloomer WD; Wyrwicz A
Anticancer Res; 2006; 26(5A):3259-63. PubMed ID: 17094438
[TBL] [Abstract][Full Text] [Related]
10. Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo.
McSheehy PM; Prior MJ; Griffiths JR
Br J Cancer; 1992 Mar; 65(3):369-75. PubMed ID: 1558790
[TBL] [Abstract][Full Text] [Related]
11. Fluorine nuclear magnetic resonance spectroscopy of human biofluids in the field of metabolic studies of anticancer and antifungal fluoropyrimidine drugs.
Malet-Martino M; Gilard V; Desmoulin F; Martino R
Clin Chim Acta; 2006 Apr; 366(1-2):61-73. PubMed ID: 16337167
[TBL] [Abstract][Full Text] [Related]
12. Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours.
McSheehy PM; Port RE; Rodrigues LM; Robinson SP; Stubbs M; van der Borns K; Peters GJ; Judson IR; Leach MO; Griffiths JR
Cancer Chemother Pharmacol; 2005 Feb; 55(2):117-28. PubMed ID: 15592719
[TBL] [Abstract][Full Text] [Related]
13. Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics.
Presant CA; Wolf W; Albright MJ; Servis KL; Ring R; Atkinson D; Ong RL; Wiseman C; King M; Blayney D
J Clin Oncol; 1990 Nov; 8(11):1868-73. PubMed ID: 2230874
[TBL] [Abstract][Full Text] [Related]
14. Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high-field 19F-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols.
Lutz NW; Naser-Hijazi B; Koroma S; Berger MR; Hull WE
NMR Biomed; 2004 May; 17(3):101-31. PubMed ID: 15137037
[TBL] [Abstract][Full Text] [Related]
15. New techniques in the pharmacokinetic analysis of cancer drugs. III. Nuclear magnetic resonance.
Maxwell RJ
Cancer Surv; 1993; 17():415-23. PubMed ID: 8137351
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate increases the activation and cytotoxicity of 5-fluorouracil: detected by 19F n.m.r. in vivo.
McSheehy PM; Prior MJ; Griffiths JR
Biochem Soc Trans; 1989 Dec; 17(6):1050. PubMed ID: 2628073
[No Abstract] [Full Text] [Related]
17. 19F magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver.
Sijens PE; Huang YM; Baldwin NJ; Ng TC
Cancer Res; 1991 Mar; 51(5):1384-90. PubMed ID: 1997177
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance spectroscopy for measuring the biodistribution and in situ in vivo pharmacokinetics of fluorinated compounds: validation using an investigation of liver and heart disposition of tecastemizole.
Schneider E; Bolo NR; Frederick B; Wilkinson S; Hirashima F; Nassar L; Lyoo IK; Koch P; Jones S; Hwang J; Sung Y; Villafuerte RA; Maier G; Hsu R; Hashoian R; Renshaw PF
J Clin Pharm Ther; 2006 Jun; 31(3):261-73. PubMed ID: 16789992
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia.
Aboagye EO; Maxwell RJ; Kelson AB; Tracy M; Lewis AD; Graham MA; Horsman MR; Griffiths JR; Workman P
Cancer Res; 1997 Aug; 57(15):3314-8. PubMed ID: 9242466
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil.
de Brauw LM; Marinelli A; van de Velde CJ; Hermans J; Tjaden UR; Erkelens C; de Bruijn EA
Cancer Res; 1991 Mar; 51(6):1694-700. PubMed ID: 1998960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
